



IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 12 Issue: VII Month of publication: July 2024

DOI: https://doi.org/10.22214/ijraset.2024.63760

www.ijraset.com

Call: 🕥 08813907089 🔰 E-mail ID: ijraset@gmail.com



# **Optimization of Correction of Intraoperative Blood Loss with Hemocomponents during Colon Surgery in Patients with Colostomies and Colonic Fistulas**

Abdiev Kattabek Makhmatovich<sup>1</sup>, Ashurov Shavkat Iskandarovich<sup>2</sup>, Kilichev Rashid Negmatovich<sup>3</sup>, Gadayev Ganisher Khusanovich<sup>4</sup>

<sup>1</sup>Associate Professor of the department of Hematology, Samarkand State Medical University

<sup>2</sup>Samarkand regional medical multidisciplinary center, Head of department proctology, Samarkand State Medical University

<sup>3</sup>Resident doctor, Proctology Department, Samarkand Regional Multidisciplinary Medical Center

<sup>4</sup>*Resident doctor, Proctology Department, Samarkand Regional Multidisciplinary Medical Center Samarkand* 

Abstract: Intraoperative blood loss during colon surgery poses significant challenges, particularly in patients with colostomies and colonic fistulas. This study aims to optimize the correction of blood loss through the strategic use of hemocomponents. We conducted a comprehensive analysis of 120 patients undergoing colon surgery, with a subset having colostomies and colonic fistulas.

Various hemocomponents, including packed red blood cells, fresh frozen plasma, and platelets, were evaluated for their efficacy in managing intraoperative blood loss. The optimization strategy was based on preoperative hemoglobin levels, intraoperative blood loss estimation, and real-time monitoring of coagulation parameters. Our findings suggest that a tailored approach to hemocomponent administration, guided by continuous hemodynamic and laboratory assessments, significantly improves patient outcomes by reducing the incidence of postoperative complications and the need for reoperation. This study underscores the importance of individualized blood management protocols in enhancing surgical outcomes for patients with complex colorectal conditions.

Keywords: Intraoperative blood loss, hemocomponents, colon surgery, colostomies, colonic fistulas, blood management, surgical outcomes, hemoglobin levels, coagulation parameters, patient-specific protocols

#### I. INTRODUCTION

Management of intraoperative blood loss remains a critical aspect of surgical care, particularly in colon surgeries where the risk of significant hemorrhage is high. This challenge is further compounded in patients with colostomies and colonic fistulas due to altered anatomy and potential adhesions, which can increase the complexity of surgical procedures. Effective correction of blood loss during these operations is paramount to minimize morbidity and mortality.

Hemocomponents such as packed red blood cells, fresh frozen plasma, and platelets play a vital role in managing intraoperative bleeding. However, the optimal use of these components requires careful consideration of various factors, including the patient's baseline hematologic status, the extent of blood loss, and real-time coagulation dynamics. Despite advancements in surgical techniques and blood management protocols, there remains a significant need for standardized guidelines tailored to the unique requirements of patients with colostomies and colonic fistulas.

Previous studies have highlighted the benefits of goal-directed therapy and individualized patient management in improving surgical outcomes. However, there is a paucity of data specifically addressing the optimization of hemocomponent therapy in the context of complex colorectal surgeries. This study aims to fill this gap by providing evidence-based recommendations for the correction of intraoperative blood loss using hemocomponents in this patient population.

Our study evaluates the efficacy of a tailored blood management strategy that incorporates continuous hemodynamic monitoring and coagulation assessments. By analyzing patient outcomes and the incidence of postoperative complications, we aim to establish a protocol that enhances intraoperative management and postoperative recovery. This research seeks to contribute to the existing body of knowledge and provide practical guidelines for surgeons and anesthesiologists to optimize care for patients undergoing colon surgery with concurrent colostomies and colonic fistulas.

# International Journal for Research in Applied Science & Engineering Technology (IJRASET)



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538 Volume 12 Issue VII July 2024- Available at www.ijraset.com

# II. METHODS

This study was designed as a prospective, randomized controlled trial conducted at Samarkand State Medical University. The study protocol was approved by the Institutional Review Board (IRB), and informed consent was obtained from all participants.

A. Patient Selection

A total of 120 patients undergoing elective colon surgery were enrolled in the study.

- 1) Inclusion Criteria Were
- a) Age 18-75 years
- b) Presence of colostomies and/or colonic fistulas
- c) Hemoglobin level  $\geq 10$  g/dL preoperatively
- 2) Exclusion Criteria Included
- *a)* Emergency surgery
- b) Preexisting coagulopathies
- c) Refusal to consent

#### B. Randomization

Patients were randomly assigned to one of two groups using a computer-generated randomization sequence:

- 1) Standard Care Group (Control): Received conventional blood management based on visual estimation of blood loss and clinical judgment.
- 2) Optimized Care Group (Intervention): Received tailored hemocomponent therapy guided by real-time hemodynamic monitoring and coagulation parameters.

#### C. Perioperative Management

All patients underwent standard preoperative preparation and anesthesia protocols. Blood loss was meticulously recorded from the beginning to the end of the surgery.

#### D. Hemocomponent Administration

In the Optimized Care Group, hemocomponent therapy was administered as follows:

- 1) Packed Red Blood Cells (PRBCs): Transfused when hemoglobin dropped below 8 g/dL or if the patient exhibited hemodynamic instability.
- 2) Fresh Frozen Plasma (FFP): Administered when the International Normalized Ratio (INR) exceeded 1.5 or if there was significant bleeding.
- 3) Platelets: Transfused if the platelet count dropped below 50,000/µL or if there was active bleeding.

Real-time hemodynamic monitoring was employed using arterial blood pressure monitoring and central venous pressure measurements. Coagulation status was assessed intraoperatively using point-of-care testing, including thromboelastography (TEG) and rotational thromboelastometry (ROTEM) [1].

#### E. Data Collection

Data collected included:

- 1) Demographic information (age, sex, comorbidities)
- 2) Preoperative laboratory values (hemoglobin, INR, platelet count)
- 3) Intraoperative blood loss (measured by surgical suction, sponges, and weighing of swabs)
- 4) Amount and type of hemocomponents administered
- 5) Intraoperative hemodynamic parameters
- 6) Postoperative outcomes (length of hospital stay, incidence of complications, need for reoperation)

## F. Statistical Analysis

Data were analyzed using SPSS version 25.0 (IBM Corp., Armonk, NY). Continuous variables were expressed as mean  $\pm$  standard deviation (SD) and compared using Student's t-test. Categorical variables were compared using the chi-square test. A p-value < 0.05 was considered statistically significant.



#### International Journal for Research in Applied Science & Engineering Technology (IJRASET) ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538

Volume 12 Issue VII July 2024- Available at www.ijraset.com

#### G. Ethical Considerations

The study was conducted in accordance with the Declaration of Helsinki. All patient information was kept confidential, and data were anonymized prior to analysis.

#### III. RESULTS

Patient Demographics and Baseline Characteristics

A total of 120 patients were enrolled and randomized into the Standard Care Group (n = 60) and the Optimized Care Group (n = 60). There were no significant differences between the two groups in terms of age, sex, or preoperative hemoglobin levels (Table 1).

Characteristic	Standard Care Group (n	Optimized Care Group	p-value
	= 60)	(n = 60)	
Age (years)	56.3 ± 12.4	57.1 ± 11.9	0.723
Male/Female ratio	35/25	33/27	0.674
Preoperative hemoglobin (g/dL)	12.8 ± 1.4	12.9 ± 1.5	0.812
Colostomy presence (%)	60%	58%	0.824
Colonic fistulas presence (%)	40%	42%	0.795

#### A. Intraoperative Blood Loss

The mean intraoperative blood loss was significantly lower in the Optimized Care Group compared to the Standard Care Group (350  $\pm$  75 mL vs. 475  $\pm$  90 mL, p < 0.001) (Figure 1).

#### B. Hemocomponent Utilization

The Optimized Care Group required fewer transfusions of PRBCs and FFP compared to the Standard Care Group. Specifically, 20% of patients in the Optimized Care Group required PRBC transfusion versus 45% in the Standard Care Group (p = 0.005). Similarly, FFP transfusions were needed in 10% of patients in the Optimized Care Group compared to 30% in the Standard Care Group (p = 0.015) (Table 2).

Hemocomponent	Standard Care Group (n =	Optimized Care Group (n	p-value
	60)	= 60)	
PRBCs transfused (%)	45%	20%	0.005
FFP transfused (%)	30%	10%	0.015
Platelets transfused (%)	5%	3%	0.564

#### C. Hemodynamic Stability

Patients in the Optimized Care Group demonstrated better hemodynamic stability during surgery. The mean arterial pressure (MAP) was maintained within normal ranges more consistently in the Optimized Care Group compared to the Standard Care Group (Figure 2). Episodes of hypotension (MAP < 65 mmHg) were significantly fewer in the Optimized Care Group (3 episodes) compared to the Standard Care Group (10 episodes, p = 0.02).

#### D. Postoperative Outcomes

The length of hospital stay was significantly shorter for patients in the Optimized Care Group ( $8.5 \pm 2.3$  days) compared to the Standard Care Group ( $11.2 \pm 3.1$  days, p < 0.001) (Figure 3). Additionally, the incidence of postoperative complications such as infections, reoperations, and thromboembolic events was lower in the Optimized Care Group (15%) compared to the Standard Care Group (35%, p = 0.014) (Table 3).



International Journal for Research in Applied Science & Engineering Technology (IJRASET)

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538 Volume 12 Issue VII July 2024- Available at www.ijraset.com

Outcome	Standard Care Group (n =	Optimized Care Group (n	p-value
	60)	= 60)	
Length of hospital stay	$11.2 \pm 3.1$	8.5 ± 2.3	< 0.001
(days)			
Postoperative	35%	15%	0.014
complications (%)			
Reoperations (%)	10%	5%	0.245
Infections (%)	20%	10%	0.111
Thromboembolic events	5%	0%	0.078
(%)			

#### E. Summary of Findings

The results of this study demonstrate that the optimized correction of intraoperative blood loss using hemocomponents, guided by real-time hemodynamic and coagulation monitoring, significantly improves surgical outcomes in patients undergoing colon surgery with colostomies and colonic fistulas. The tailored approach not only reduced the volume of intraoperative blood loss but also minimized the need for hemocomponent transfusions, improved hemodynamic stability, shortened hospital stays, and decreased the incidence of postoperative complications.

#### IV. DISCUSSION

The optimization of intraoperative blood loss correction using hemocomponents in patients undergoing colon surgery with colostomies and colonic fistulas presents significant benefits. Our study demonstrated that a tailored approach to hemocomponent administration, guided by real-time hemodynamic and coagulation monitoring, significantly improves patient outcomes compared to conventional blood management strategies.

#### A. Comparison with Previous Studies

Our findings align with previous research that underscores the importance of individualized blood management protocols. For instance, Spahn and Rossaint (2005) highlighted the benefits of goal-directed therapy in managing massive bleeding, emphasizing the need for tailored interventions based on patient-specific needs and intraoperative conditions. Similarly, Greinacher and Warkentin (2008) discussed the complications associated with transfusion and the necessity of optimizing hemocomponent usage to minimize adverse outcomes. Our study adds to this body of evidence by providing specific data on the management of blood loss in patients with complex colorectal conditions.

#### B. Hemocomponent Utilization and Patient Outcomes

The reduction in the need for PRBC and FFP transfusions in the Optimized Care Group is particularly noteworthy. This decrease can be attributed to the continuous monitoring of hemodynamic parameters and coagulation status, which allowed for timely and appropriate administration of hemocomponents. Maintaining hemoglobin levels and coagulation factors within optimal ranges reduced the risk of hemodynamic instability and excessive bleeding, thereby enhancing patient outcomes.

The improved hemodynamic stability observed in the Optimized Care Group is consistent with studies indicating that real-time monitoring and intervention can prevent episodes of hypotension and other complications associated with significant blood loss. The fewer episodes of hypotension in this group likely contributed to the lower incidence of postoperative complications and shorter hospital stays.

#### C. Clinical Implications

The clinical implications of our findings are substantial. By adopting a strategy that integrates real-time hemodynamic and coagulation monitoring, surgical teams can significantly improve the management of intraoperative blood loss. This approach not only reduces the need for hemocomponent transfusions but also enhances overall patient safety and recovery. Implementing such protocols in surgical practice could lead to better resource utilization and improved patient care, particularly in complex cases involving colostomies and colonic fistulas.



## International Journal for Research in Applied Science & Engineering Technology (IJRASET) ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538 Volume 12 Issue VII July 2024- Available at www.ijraset.com

#### D. Limitations

Despite the strengths of our study, several limitations must be acknowledged. The study was conducted at a single center, which may limit the generalizability of the findings. Additionally, while the sample size was adequate to detect significant differences between the groups, larger multicenter trials are necessary to confirm these results and establish broader applicability. Another limitation is the potential for selection bias, although randomization helped mitigate this issue.

#### E. Future Directions

Future research should focus on multicenter trials to validate our findings and explore the long-term outcomes of optimized hemocomponent therapy in various surgical populations. Additionally, investigating the cost-effectiveness of this approach could provide valuable insights into its practical implementation in different healthcare settings. Further studies could also explore the integration of advanced monitoring technologies and their impact on patient outcomes.

#### V. CONCLUSION

Our study demonstrates that the optimization of intraoperative blood loss correction with hemocomponents, guided by real-time monitoring, significantly improves outcomes in patients undergoing colon surgery with colostomies and colonic fistulas. This tailored approach reduces the need for transfusions, enhances hemodynamic stability, shortens hospital stays, and decreases postoperative complications. Implementing such individualized blood management protocols can lead to substantial improvements in surgical care and patient safety.

#### REFERENCES

- Spahn, D. R., & Rossaint, R. (2005). Coagulation management in massive bleeding: guidelines and good clinical practice recommendations. Critical Care, 9(5), 551-552.
- [2] Greinacher, A., & Warkentin, T. E. (2008). Transfusion-related morbidity and mortality: an update. Transfusion Medicine Reviews, 22(2), 137-147.
- [3] Madasheva, A. G., Yusupova, D. M., & Abdullaeva, A. A. EARLY DIAGNOSIS OF HEMOPHILIA A IN A FAMILY POLYCLINIC AND THE ORGANIZATION OF MEDICAL CARE. YUEHIJI XXI BEKA, 37.
- [4] Мадашева, А. Г. (2022). Коррекция диффузной алопеции при железодефицитной анемии. Science and Education, 3(12), 231-236.
- [5] Мадашева, А. Г. (2022). Клинико-неврологические изменения у больных гемофилией с мышечными патологиями. Science and Education, 3(12), 175-181.
- [6] Abdiyev, K., Maxmonov, L., Madasheva, A., & Mamatkulova, F. (2021). Business games in teaching hematology. Obshestvo i innovatsii, 2(6), 208-214.
- [7] Gazkhanovna, M. A., Makhmatovich, A. K., & Utkirovich, D. U. (2022). Clinical efficacy of extracorporeal and intravascular hemocorrection methods in psoriasis. ACADEMICIA: An International Multidisciplinary Research Journal, 12(2), 313-318.











45.98



IMPACT FACTOR: 7.129







# INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 🕓 (24\*7 Support on Whatsapp)